Cannabis and TMJ Pain
Reviewing cannabis for jaw joint and muscle pain with honest assessment of weak evidence.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
One small trial found topical CBD reduced jaw pain in the masseter muscle, but it hasn't been replicated. Everything else—oral CBD, smoking flower, 'relaxing' strains—is extrapolation from broader pain research or anecdote. Standard treatments (splints, physical therapy, NSAIDs) have real evidence and should come first. Cannabis might be an adjunct for people who've already tried proven options, but don't expect it to replace them.
Not Medical Advice
This article is not medical advice. It is an evidence review for educational purposes. Temporomandibular disorders have multiple causes—muscular, joint-structural, dental, postural, psychological, or combinations—and treatment depends on the underlying driver. Speak with a dentist, orofacial pain specialist, or physician before adding cannabis to your regimen, especially if you are pregnant, take other medications, have a history of psychosis, cardiovascular disease, or cannabis use disorder.
Plain-Language Summary
Temporomandibular disorder (TMD) refers to pain and dysfunction in the jaw joint and the muscles controlling it. Symptoms include jaw pain, clicking or popping, limited opening, headache, and referred ear pressure. About 5–12% of adults experience TMD at any given time [1] Strong evidence.
People ask whether cannabis helps because (1) cannabinoids are known to modulate pain and muscle tone, (2) many TMD cases involve nighttime clenching (bruxism) and cannabis can be sedating, and (3) standard treatments do not work for everyone.
The honest answer: research is sparse. One small randomized trial found topical CBD reduced jaw pain [2] Weak / limited. Everything else—vaping, smoking, oral CBD—comes from extrapolation of broader chronic pain research or patient anecdotes, not direct evidence in TMD. If you choose to try it, do so with realistic expectations and ideally with your dentist's knowledge.
What Probably Works
Honest assessment: nothing has 'probably works' evidence specifically for TMD. No cannabis formulation has been studied at the level needed to establish that claim for jaw pain.
The closest candidate is topical CBD applied to the masseter muscle for myofascial TMD pain. In 2019, Nitecka-Buchta and colleagues published a double-blind randomized trial applying 10% CBD cream to the masseter twice daily for 14 days in 60 patients with myofascial TMD pain. They reported a ~70% reduction in pain intensity and reduced masseter muscle activity (EMG) compared with placebo [2] Weak / limited. This is a single study from one research group, not independently replicated in larger cohorts, so the evidence remains weak rather than strong.
For general chronic pain (not TMD specifically), oral cannabinoids show modest pain reduction in neuropathic pain and spasticity [3][4] Strong evidence. Whether this translates to jaw pain is unknown—a frequent gap in pain research.
What Might Work
Cannabinoids for muscular TMD. Many TMD cases involve tension and dysfunction of the masseter, temporalis, and pterygoid muscles. Nabiximols (Sativex) is approved for multiple sclerosis spasticity because it reduces skeletal muscle tone [4] Strong evidence. Whether this effect generalizes to jaw musculature in otherwise healthy people is unstudied. Weak / limited
CBD for anxiety-driven bruxism. Bruxism contributes to many TMD cases. CBD shows mixed evidence for anxiety and sleep [5] Weak / limited. If anxiety is a primary driver of clenching, treating the anxiety might indirectly reduce jaw symptoms. No trial has directly tested this hypothesis in TMD patients. Weak / limited
Low-dose THC at night for pain and sleep. Chronic pain patients commonly report better sleep with evening THC use [6] Anecdote. Improved sleep could secondarily reduce TMD symptom severity or flares. This is mechanistic reasoning, not direct evidence for TMD. Anecdote
CBD for inflammatory TMD (synovitis, osteoarthritis). Some TMD involves true joint inflammation. CBD shows anti-inflammatory effects in animal arthritis models [7], but human trials in joint disease are limited and the temporomandibular joint has never been the specific target. Weak / limited
What Doesn't Work, or Has Weak Evidence
Smoking flower as a treatment plan. Inhaled cannabis has a short duration (2–4 hours) and peaks quickly, making it poor pharmacology for a chronic, often nocturnal condition. Acute symptom relief during use is real, but tolerance develops and it does not address the underlying disorder. Anecdote
Choosing an 'indica strain' for jaw tension. The indica-versus-sativa framework is unreliable for predicting effects [8] Strong evidence. Picking a product labeled 'indica' to relax your jaw is folklore. Chemovar (cannabinoid and terpene profile) matters more than the label, but even then, human clinical effects of specific terpenes remain largely unproven. See Cannabis and Polypharmacy Risks for interactions. No data
'High-myrcene strains for muscle relaxation.' The claim that myrcene above 0.5% causes sedation or 'couch-lock' is industry folklore without clinical trial support [9] No data. Do not choose a product for TMD based on myrcene content.
CBD gummies for jaw pain. Oral CBD has poor bioavailability (~6%) [10] and consumer gummies typically contain 10–25 mg—well below the hundreds of milligrams used in clinical trials. Could it help a little? Possibly. The dose-response data is absent. Weak / limited
What We Don't Know
- Whether the Nitecka-Buchta topical CBD finding replicates in larger, independent studies.
- Whether THC, CBD, or a combination is superior for different TMD subtypes (myofascial, disc displacement, osteoarthritis).
- Optimal dose, route (topical, oral, inhalation), and treatment duration.
- Whether long-term cannabis use worsens bruxism. Cannabis withdrawal disrupts sleep [11] Strong evidence, and some users report increased clenching during tolerance breaks, but TMD patients have not been formally studied. Anecdote
- Drug interactions with common TMD medications (cyclobenzaprine, amitriptyline, NSAIDs, benzodiazepines). CBD inhibits CYP3A4 and CYP2C19 [12] and can raise blood levels of co-administered drugs. See Cannabis and Polypharmacy Risks. Strong evidence
- Whether chronic cannabis inhalation aggravates TMD via jaw posture during smoking or vaping. Plausible but unstudied. No data
- Long-term safety in orofacial disease.
Comparison With Standard Treatments
Standard first-line care for TMD has robust evidence and should generally be tried first:
- Self-care and education (soft diet, jaw rest, posture, heat): effective for many mild cases [1] Strong evidence.
- Occlusal splints (night guards): moderate to strong evidence for reducing pain and protecting teeth from bruxism [13] Strong evidence.
- Physical therapy and jaw exercises: strong evidence, comparable to or better than other single interventions [14] Strong evidence.
- NSAIDs (short-term): strong evidence for acute symptom relief; not ideal for long-term use Strong evidence.
- Tricyclic antidepressants (e.g., low-dose amitriptyline): weak to moderate evidence for chronic orofacial pain [15] Weak / limited.
- Cognitive behavioral therapy (CBT): strong evidence for pain and bruxism, especially when anxiety is a driver Strong evidence.
- Botulinum toxin to masseter: growing but mixed evidence; considered when other measures fail Weak / limited.
Cannabis has lower evidence quality than all of these for TMD specifically. It is reasonable to consider cannabis as an adjunct after standard care has been tried, not as a first-line or replacement therapy.
Risks and Practical Considerations
- Cannabis use disorder and dependence: roughly 1 in 10 adult users develop CUD; higher with daily use [16] Strong evidence.
- Cognitive and driving impairment: THC causes short-term impairment. Do not drive or operate machinery. Strong evidence
- Cardiovascular effects: THC raises heart rate and can precipitate cardiac events in vulnerable individuals Strong evidence.
- Psychiatric effects: THC can worsen anxiety and, in predisposed people, increase risk of psychosis Strong evidence. Anxiety itself drives bruxism, so monitor whether THC is helping or worsening your symptoms.
- Drug interactions: CBD inhibits CYP3A4 and CYP2C19 [12] Strong evidence. If you take other medications, review with a pharmacist.
- Liver enzyme elevations: high-dose CBD can elevate liver transaminases [17] Strong evidence.
- Oral health: chronic cannabis smoking is associated with gum disease, dry mouth, and periodontal problems Strong evidence. This is particularly relevant for a dental condition.
Practical suggestion if you and your clinician decide to try cannabis: Start with a single intervention (e.g., topical CBD applied to the masseter) for a defined trial period of 2–4 weeks. Keep a daily pain and clenching log. Stop if you see no clear benefit. Do not add cannabis while simultaneously changing multiple other treatments—you will not know what worked. See THC Dose and Anxiety if THC-related anxiety emerges.
Sources
- Peer-reviewed Valesan LF, et al. (2021). Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clinical Oral Investigations, 25(2), 441–453.
- Peer-reviewed Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. (2019). Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. Journal of Clinical Medicine, 8(11), 1886.
- Government National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press.
- Peer-reviewed Whiting PF, et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA, 313(24), 2456–2473.
- Peer-reviewed Shannon S, Lewis N, Lee H, Hughes S (2019). Cannabidiol in anxiety and sleep: a large case series. The Permanente Journal, 23, 18-041.
- Peer-reviewed Babson KA, Sottile J, Morabito D (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
- Peer-reviewed Hammell DC, et al. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 20(6), 936–948.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N (2022). The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE, 17(5), e0267498.
- Peer-reviewed Russo EB (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Peer-reviewed Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365.
- Peer-reviewed Bonnet U, Preuss UW (2017). The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation, 8, 9–37.
- Peer-reviewed Brown JD, Winterstein AG (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed Riley P, Glenny AM, Worthington HV, et al. (2020). Oral splints for temporomandibular disorder or bruxism: a systematic review. British Dental Journal, 228(3), 191–197.
- Peer-reviewed Armijo-Olivo S, et al. (2016). Effectiveness of manual therapy and therapeutic exercise for temporomandibular disorders: systematic review and meta-analysis. Physical Therapy, 96(1), 9–25.
- Peer-reviewed Häggman-Henrikson B, et al. (2017). Pharmacological treatment of orofacial pain — health technology assessment including a systematic review with network meta-analysis. Journal of Oral Rehabilitation, 44(10), 800–826.
- Government Substance Abuse and Mental Health Services Administration (SAMHSA). 2022 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.
- Government U.S. Food and Drug Administration (2018). Epidiolex (cannabidiol) prescribing information and clinical review.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Arthritis Pain — Cannabis may help arthritis pain and sleep, but doesn't replace disease-modifying drugs fo...
- Cannabis and Chronic Pain — Evidence summary of cannabis for chronic pain: modest benefit for some, real risks, and ho...
- Cannabis and Dental Pain — Evidence for cannabis in acute and chronic dental pain, compared to standard treatments.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis for Chronic Diarrhea — Small evidence of symptom relief in IBD, but not a disease-modifying treatment; serious ri...
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...